NEW YORK, March 14 - Calling his move to InforMax a "no-brainer," Andrew Whiteley, the company's newly appointed president, chairman, and CEO, said he is excited about the future of bioinformatics and plans immediately to bolster his company's marketing efforts.
Speaking to investors and journalists in a conference call on Thursday morning, Whiteley said he has given himself 90 days to assess the company and flesh out his leadership strategy as he prepares to move into Alex Titomirov's old office on April 1.
"We're very focused at developing what I call a robust product strategy in software and services" that help the company become profitable in the future, said Whiteley. "Certainly we need to strengthen [the marketing side] of the organization, and we will be seeking to do that."
He said that J Rollins, vice president of sales and marketing, "continues to do a great job for us in managing the sales group." But on the marketing side, Whiteley stressed that "we need to fill a position ... at a senior level in order to really progress. It's not been a functional part of InforMax so far, but I certainly intend to make it so."
Plans for R&D were a bit murkier. Asked to describe his strategy for the product side of the business, Whiteley said that InforMax must ensure that "charting a path to profitability ... we've got to ensure that we're balancing the investment we're making in R&D in a way that's sustainable in the context of our sales."
Asked by GenomeWeb about the likelihood of hiring new bioinformaticists or opening new R&D facilities in the short term, John Green, COO and CFO interjected and said: "We're always looking to continue to upgrade ... [our R&D group]. We have a lot of interest from really top talent" to join the company.